LV-NYESO TCR/sr39TK PBSC

Developed for: high grade malignant neoplasm · sarcoma
Investigated by: California Institute for Regenerative Medicine (CIRM) · Jonsson Comprehensive Cancer Center

today NCT03240861 · Ph 1

2018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT03240861	Jul 2017 → Oct 2023	high grade malignant neoplasm, sarcoma	Jonsson Comprehensive Cancer Center	Terminated	No outcome recorded Stop: Enrollment

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	LV-NYESO TCR/sr39TK PBSC	“Patients receive LV-NYESO TCR/sr39TK PBSC IV on day 0” NCT03240861 ↗
Route	Intravenous	“Patients receive LV-NYESO TCR/sr39TK PBSC IV on day 0” NCT03240861 ↗